Personalis Inc Stock
€4.72
Your prediction
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Not a member yet? Sign up for free!
Financial data and news for Personalis
sharewise wants to provide you with the best news and tools for Personalis, so we directly link to the best financial data sources.
Financials
News
Why Tempus AI Stock Skyrocketed Nearly 22% Today
Niche artificial intelligence (AI) company Tempus AI (NASDAQ: TEM) is a stock recently listed on the exchange that is making significant moves. On news that one of these was a strategic investment
ESMO 2024 Data Expands on Compelling Performance of Personalis NeXT Personal® MRD Test
Personalis, Inc. (Nasdaq: PSNL), a leader in MRD testing, announced findings presented this week at the European Society of Medical Oncology Congress (ESMO) Congress 2024 in Barcelona, Spain
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors granted, on August 15, 2024, a
ASCO Data Highlights NeXT Personal® Ultra-sensitive MRD Performance in Early-stage Breast Cancer Recurrence Detection and Immunotherapy Monitoring
Personalis, Inc. (Nasdaq: PSNL) announced today that data presented at the American Society for Clinical Oncology (ASCO) oral podium talks in Chicago, IL demonstrated that the Personalis NeXT
Personalis Announces Start of Cancer MRD Testing Commercialization Collaboration with Tempus
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today the commencement of commercialization efforts by Tempus for NeXT Personal®, Personalis’
Personalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that two podium presentations and multiple posters featuring data for the company’s NeXT
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors granted, on May 15, 2024, a
Biotech Stock Soars 60% in 2024: Cathie Wood’s Bold Investment
In just ten days, shares of the mid-cap healthcare stock Tempus AI (NASDAQ: TEM) have gone from down 4% to up nearly 60% in 2024. Famed investor Cathie Wood recently increased her allocation to
